Lawrence Eichenfield, MD

Late-breaking phase 2 findings presented at AAD show nemolizumab achieved high EASI-90 rates and rapid itch relief in pediatric patients with atopic dermatitis.

Experts discuss effective strategies for managing atopic dermatitis, emphasizing the importance of treatment adherence and quality of life improvements.

Explore effective management strategies for pediatric atopic dermatitis, focusing on treatment options and patient experiences for optimal care.

Parents of children with chronic skin conditions seek guidance on managing flares and long-term treatment strategies for better outcomes.

Experts discuss effective eczema management for young children, emphasizing treatment options, parental education, and the importance of long-term care strategies.

A pediatric case highlights the challenges of managing severe atopic dermatitis in infants, emphasizing the need for effective treatment strategies.

An 18-month-old with severe atopic dermatitis experiences rapid flare-ups, prompting a discussion on treatment options and potential triggers.

Explore effective management strategies for atopic dermatitis in children, focusing on non-steroidal options and addressing parental concerns.

Healthcare professionals discuss effective educational strategies for managing chronic skin conditions, emphasizing proactive treatment and patient understanding.

Healthcare professionals discuss effective educational strategies for managing chronic skin conditions, emphasizing proactive treatment and patient understanding.

Explore the innovative role of PDE4 inhibitors in treating atopic dermatitis, highlighting breakthroughs in topical therapies and their efficacy.

Explore the innovative role of PDE4 inhibitors in treating atopic dermatitis, highlighting breakthroughs in topical applications and their efficacy.

Healthcare professionals discuss the balance of safety and effectiveness in prescribing topical steroids and non-steroidal treatments for pediatric patients.

Explore the evolving landscape of pediatric atopic dermatitis treatment, focusing on innovative therapies and strategies to break the steroid cycle.

Experts explore innovative treatments for pediatric atopic dermatitis, emphasizing non-steroidal options and early intervention for better long-term management.

Panelists discuss how OX40-pathway therapies may serve as first-line treatments after topicals due to their promising efficacy and safety profiles, though questions remain about optimal patient selection, long-term safety, and predictive biomarkers.

Panelists discuss how multiple OX40 pathway–targeted drugs are in development, including rocatinlimab (anti-OX40, cell depleting) and amlitelimab (anti-OX40L, nondepleting), both showing promising phase 2/3 results with potential for sustained responses.

The FDA has approved roflumilast 0.05% cream for atopic dermatitis in children aged 2 years and older, extending its use to a critical pediatric population.

Panelists discuss how OX40 pathway–targeted therapies may benefit specific patient subsets with particular immunologic profiles and could potentially modify the disease course when used early, although patient selection criteria remain unclear.

Panelists discuss how the OX40-OX40L costimulatory pathway represents a promising upstream target for atopic dermatitis treatment by modulating T-cell survival, expansion, and memory formation rather than targeting downstream cytokines. Panelists discuss how targeting the OX40-OX40L pathway could potentially provide broader therapeutic effects across multiple T-cell subsets and offer more durable responses than current cytokine-specific or JAK inhibitor approaches.

Panelists discuss how the OX40-OX40L costimulatory pathway represents a promising upstream target for atopic dermatitis treatment by modulating T-cell survival, expansion, and memory formation rather than targeting downstream cytokines.

Panelists discuss how atopic dermatitis involves complex T-cell–mediated immune dysfunction beyond just Th2 pathways, with antigen-presenting cells driving naive T-cell activation and differentiation into multiple T-cell subsets that produce various inflammatory cytokines.

Panelists discuss how atopic dermatitis exhibits tremendous heterogeneity in clinical presentation, disease course, symptom variability, environmental triggers, and underlying immunologic and genetic factors that contribute to the challenge of developing one-size-fits-all treatments.

Panelists discuss how despite recent therapeutic advances in atopic dermatitis treatment, significant unmet needs remain including partial responses, lack of long-term stable control, and the need for broader patient response rates and deeper clearance levels.

Eichenfield discussed the ever-evolving armamentarium, and how to navigate changes in the field.

Eichenfield discusses safety, lab monitoring, and treatment positioning of icotrokinra in adolescents with moderate to severe plaque psoriasis.

Eichenfield discusses high skin clearance and safety in teens with psoriasis, per new ICONIC-LEAD phase 3 data.

Panelists discuss the areas of research that need more attention in pediatric atopic dermatitis (AD) management, highlighting gaps in understanding the long-term effects of treatments, the genetic underpinnings of the disease, and strategies for improving early diagnosis and personalized care.

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.